Gossamer Bio Reacquires Global Rights to Seralutinib
San Diego, California, July 27, 2026 Gossamer Bio, Inc. announced a series of significant regulatory, strategic, and financial milestones...
Regulatory Update
Advertisement
AnHorn Medicines Advances AH-008 into Phase I Trial for CIPN Prevention
Irvine, California, USA — July 27, 2026 July 27, 2026 – AnHorn Medicines has announced the successful first subject...
Zevra Therapeutics to Seek EU Re-Examination for Arimoclomol After CHMP Opinion
BOSTON – July 24, 2026 Zevra Therapeutics, Inc. has announced that the European Medicines Agency’s (EMA) Committee for Medicinal...
FDA Moves to Revoke Two Petroleum-Based Food Color Additives
WASHINGTON, D.C., July 22, 2026 The U.S. Food and Drug Administration (FDA) has announced two significant regulatory actions aimed...
VERAXA Achieves Key Regulatory Milestone for BiTAC-TCE
ZURICH, Switzerland, July 20, 2026 VERAXA Biotech AG (NASDAQ: VRXA) announced that it has received Scientific Advice from Germany’s...
Advertisements
USDA FSIS Updates Food Safety Policies and Sampling Data
WASHINGTON, D.C., April 3, 2026 The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) has released its...
OST-HER2 Regulatory Progress Advances Osteosarcoma Care
NEW YORK, NEW YORK, UNITED STATES — February 17, 2026 OS Therapies has announced a major global regulatory update...
FDA Advances Tradipitant Review for Motion Sickness Relief
Washington, D.C., November 28, 2025 In a significant regulatory development, Vanda Pharmaceuticals Inc. has announced major progress on tradipitant,...
TREMFYA® Shows 96-Week Remission in Crohn’s Disease with Fully Subcutaneous Regimen
Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...
FDA Updates RINVOQ® Label for Inflammatory Bowel Disease Use
NORTH CHICAGO, Illinois, October 13, 2025 – AbbVie Inc. (NYSE: ABBV) announced that the U.S. Food and Drug Administration...
Advertisement
